 |
ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company’s website.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
[email protected]
ข่าวที่เกี่ยวข้อง
- Global Times: Xi, Trump hold talks, agree on new vision for bilateral ties
- Infinix NOTE 60 SERIES Garners Red Dot and iF Awards, Redefining Premium Smartphone Design
- EZGO Announces 1-for-150 Reverse Share Split Effective May 19, 2026
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
